In fact, although all the biguanides to date tested as inhibitory of CLIC1 activity in GSCs are not completely satisfactory as far as pharmacokinetics and long term tolerability, we believe that this information might pave the way for the identification of novel structurally-related molecules, which in future will provide a better clinical outcome for GBM. The gene discussed is CLIC1; the disease is glioblastoma.